{"id":"cytarabine-hd","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neurotoxicity (at high doses)"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2447907","moleculeType":"Unknown","molecularWeight":"1365.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine (ara-C) is a nucleoside analog that mimics cytidine and is phosphorylated intracellularly to its active triphosphate form. This active metabolite is incorporated into DNA during synthesis, causing chain termination and inhibition of DNA polymerase. It is primarily used in hematologic malignancies where rapidly dividing cells are particularly susceptible to its cytotoxic effects.","oneSentence":"Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:17.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Lymphoma"},{"name":"Chronic myeloid leukemia (CML) in blast phase"}]},"trialDetails":[{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT04931368","phase":"PHASE3","title":"OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klinikum Stuttgart","startDate":"2021-06-28","conditions":"Primary Central Nervous System Lymphoma","enrollment":331},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT00534469","phase":"PHASE2","title":"Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-02-08","conditions":"Leukemia","enrollment":60},{"nctId":"NCT07159620","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Adult T-cell Leukemia/Lymphoma","enrollment":27},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT06257394","phase":"PHASE2","title":"Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea","status":"RECRUITING","sponsor":"Hyoung Jin Kang","startDate":"2024-10-20","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":74},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT01865110","phase":"PHASE3","title":"R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-11","conditions":"Mantle Cell Lymphoma","enrollment":623},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT01527149","phase":"PHASE2","title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-12-06","conditions":"Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT03504410","phase":"PHASE3","title":"Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML","status":"TERMINATED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2018-11-12","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT01458730","phase":"PHASE2","title":"Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-05","conditions":"Central Nervous System Lymphoma","enrollment":66},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT04326439","phase":"PHASE2","title":"AflacLL1901 (CHOA-AML)","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-24","conditions":"Acute Myeloid Leukemia, AML, Childhood","enrollment":8},{"nctId":"NCT05274139","phase":"PHASE2","title":"Treatment of Primary CNS Lymphoma ( FTD )","status":"COMPLETED","sponsor":"Mingzhi Zhang","startDate":"2017-03-02","conditions":"Primary CNS Lymphoma (PCNSL)","enrollment":20},{"nctId":"NCT04174612","phase":"PHASE3","title":"AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-04-24","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":172},{"nctId":"NCT04083066","phase":"PHASE4","title":"Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2019-09-05","conditions":"Primary Central Nervous System Lymphoma","enrollment":20},{"nctId":"NCT00098839","phase":"PHASE1, PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":134},{"nctId":"NCT02676856","phase":"NA","title":"Hematopoietic Stem Cell Microtransplantation for in AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT00355199","phase":"PHASE3","title":"Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.","status":"COMPLETED","sponsor":"Gruppo Italiano Terapie Innovative nei Linfomi","startDate":"2005-05","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":246},{"nctId":"NCT02848183","phase":"PHASE2","title":"Optimal Treatment Strategy Based on for Pediatric AML","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-01","conditions":"Pediatric Acute Myeloid Leukemia","enrollment":350},{"nctId":"NCT00495287","phase":"PHASE3","title":"A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Northern Italy Leukemia Group","startDate":"2006-11","conditions":"Acute Myelogenous Leukemia","enrollment":573},{"nctId":"NCT01321346","phase":"PHASE1","title":"A Study Of Panobinostat In Children With Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2011-03","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease","enrollment":30},{"nctId":"NCT00085709","phase":"PHASE3","title":"S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2004-07","conditions":"Leukemia","enrollment":637},{"nctId":"NCT01960192","phase":"PHASE4","title":"Treatment of Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2012-06","conditions":"Primary CNS Lymphoma (PCNSL)","enrollment":50},{"nctId":"NCT00015873","phase":"PHASE3","title":"Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dutch Childhood Oncology Group","startDate":"1999-05","conditions":"Leukemia","enrollment":350},{"nctId":"NCT02024308","phase":"PHASE4","title":"AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2010-11","conditions":"Acute Myeloid Leukemia, AML1-ETO Fusion Protein Expression","enrollment":62},{"nctId":"NCT00005977","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-09","conditions":"Leukemia, Lymphoma","enrollment":83},{"nctId":"NCT01230983","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-06","conditions":"Cardiac Toxicity, Leukemia, Lymphoma","enrollment":573},{"nctId":"NCT01665014","phase":"PHASE2","title":"Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice","startDate":"2012-08","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01083342","phase":"PHASE2","title":"High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-01","conditions":"CNS Lymphoma","enrollment":36},{"nctId":"NCT01148173","phase":"PHASE2","title":"High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2007-10","conditions":"Lymphoma, Non-Hodgkin","enrollment":30},{"nctId":"NCT00946374","phase":"PHASE2","title":"Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2004-07","conditions":"Mantle-Cell Lymphoma","enrollment":20},{"nctId":"NCT00880243","phase":"PHASE3","title":"Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Acute Leukemia French Association","startDate":"1999-03","conditions":"Acute Myeloid Leukemia","enrollment":473},{"nctId":"NCT00131027","phase":"PHASE3","title":"High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)","status":"UNKNOWN","sponsor":"Japan Adult Leukemia Study Group","startDate":"2002-09","conditions":"Lymphoblastic Leukemia, Acute","enrollment":240},{"nctId":"NCT00558220","phase":"PHASE2","title":"R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Czech Lymphoma Study Group","startDate":"2002-05","conditions":"Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma, Follicular Lymphoma Grade III","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cytarabine HD","genericName":"Cytarabine HD","companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytarabine HD is used in the treatment of various conditions, including Central Nervous System Lymphoma, Lymphoma, Pediatric Acute Myeloid Leukemia, and Stage I and Stage II Contiguous Mantle Cell Lymphoma. It is administered as part of immunochemotherapy regimens, often in combination with other medications such as Rituximab, HD-MTX, Cyclophosphamide, and Ifosfamide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}